Highest-materiality recent filing
EBR Systems raises A$150M via placement and entitlement offer at A$0.38/CDI
Total capital raise of A$150M: A$64.4M placement (Tranche 1 & 2) and A$85.6M entitlement offer.
EBR Systems Q1 preliminary revenue $2.25-$2.36M; commercial cases double QoQ
Preliminary unaudited Q1 2026 revenue $2.25M-$2.36M; financial close not yet complete.
EBR Systems shareholders approve reverse stock split (1:5-1:20) and 55.9M CDI issuance
Reverse stock split proposal passed with 233.2M for, 970K against; board may set ratio 1:5 to 1:20 or abandon.
Preliminary Q4 revenue $870K-$935K; FY2025 revenue $1,552K-$1,617K (unaudited, subject to audit adjustments).
EBR Systems raises ~$36M via 55.9M CDI placement at A$1.00 per CDI
Issued 55.9M CDIs at A$1.00 (~US$0.6434), raising ~US$36M gross before ~$2.25M fees.
CMS proposes NTAP reimbursement for EBR's WiSE CRT at max 65% rate
CMS proposed NTAP for WiSE CRT System for FY 2026 at maximum add-on payment of 65% of device cost.
FDA approves EBR Systems' WiSE CRT System for commercial distribution in US
FDA approved WiSE CRT System for left ventricular endocardial pacing; target initial US addressable market ~$3.6B.
On August 21, 2026, EBR Systems, Inc. (the “Company”) announced the impending departure of Erik Strandberg, Chief Commercial Officer, who will be leaving the Company in the coming months,
Max materiality 0.90 · Median 0.60 · Most common event other_material